Mitochondrial ROS-induced ROS release: an update and review
The second trial, conducted at Peking University Third Hospital (Ethical code: D2020188), was a Phase I clinical triala randomized, double-blind, controlled study aimed at assessing the safety and preliminary efficacy of DPSC therapy at varying dose concentrations, carried out from July 31, 2021, to December 24, 2022
Repeated activation could ensure a population of inflammation-predisposed microglia vigilant for recurring infection
B cell-derived anti-beta 2 glycoprotein I antibody mediates hyperhomocysteinemia-aggravated hypertensive glomerular lesions by triggering ferroptosis
Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study